Laura is the editorial director of The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®'s parent company, MJH Life Sciences, since 2011. She has an MA in business and economic reporting from New York University.
There are no cures available to patients with polycythemia vera (PV), who are first treated with hydroxyurea (HU); ruxolitinib is approved as a second-line therapy in both Europe and the United States for patients who are intolerant of or resistant to HU. Two abstracts being presented at the 61st American Society of Hematology Annual Meeting & Exposition explore the use of ruxolitinib in patients with PV, either in patients who first tried HU or had ruxolitinib as a first-line therapy.
There are no cures available to patients with polycythemia vera (PV), who are first treated with hydroxyurea (HU); ruxolitinib is approved as a second-line therapy in both Europe and the United States for patients who are intolerant of or resistant to HU. Two abstracts being presented at the 61st American Society of Hematology Annual Meeting & Exposition in Orlando, Florida, explore the use of ruxolitinib in patients with PV.
The first abstract1 analyzed use of ruxolitinib in newly diagnosed patients with PV. The German study Ruxo-BEAT treated 28 patients with ruxolitinib for at least 6 months. It was a multicenter, open-label, 2-arm phase 2b trial. Another 22 patients received best available therapy. There was the opportunity for crossover between the 2 arms after 6 months.
For the patients receiving ruxolitinib, the mean hematocrit level decreased from 45.9+/—5.6% to 41.0+/–5.0% after 6 months of treatment. The mean JAK2V617F allele burden decreased from 50.2+/28.4% to 44.0+/–28.5%. The percentage of patients with night sweats had decreased from 30% to 11% and the percentage with pruritus decreased from 41% to 26%.
Recruitment into this trial is ongoing.
In the second abstract,2 the researchers analyzed why patients were switched from HU to ruxolitinib and described real-world dosing patterns. They conducted a retrospective medical chart review at practices in the Cardinal Health Oncology Provider Extended Network. Patients had started ruxolitinib between January 1, 2015, and December 31, 2016, and had previously been treated with HU for at least 3 months. They were at least 18 years old and were seen 2 or more times during the 6 months after starting ruxolitinib.
Overall, 99 patients were included and 99% of them were positive for the JAK2V617F mutation. More than a quarter (28%) of patients had reached a HU dose of ≥2 g/d by the time they discontinued HU. Most commonly, patients discontinued HU because of resistance (63%), followed by intolerance (17%), both resistance and intolerance (11%), and other reasons (9%).
Less than half (44%) of patients started ruxolitinib at the recommended dose of 10 mg twice daily. Within 6 months, 19 of those patients (43%) modified their dose: 13 (30%) had their dose increased, 5 (11%) had the dose decreased, 1 (2%) had the dose interrupted. After the 6 months, these patients needed fewer dose modifications.
Of those patients who discontinued ruxolitinib, 65% had no dosing changes during their treatment.